Not only has the bloom left the rose of the biotech boom, investors have
started plucking off the petals too. That has led to bowel-clenching
declines for many biotechs, including Alnylam Pharmaceuticals (NASDAQ: ALNY )
. While the market is going to do what it's going to do, Alnylam has an
uncommonly deep pipeline, with multiple rare disease shots on goal and
strong delivery technology in a therapeutic area where many Big Pharmas
have thrown in the towel.
Read the full article here:
Alnylam Pharmaceuticals, Inc. Managing Multiple Irons In The Fire
No comments:
Post a Comment